Author:
Abatay Sel Figen,Erol Ayse,Suleymanoglu Mediha,Kuruca Durdane Serap,Savran Oguz Fatma
Reference26 articles.
1. Friedenstein AJ, Deriglasova UF, Kulagina NN et al (1974) Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 2(2):83–92
2. Markov A, Thangavelu L, Aravindhan S et al (2021) Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther 12(1):192
3. Zhu R, Yan T, Feng Y et al (2021) Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms. Cell Res 31(12):1244–1262
4. Lanzoni G, Linetsky E, Correa D et al (2021) Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med 10(5):660–673
5. Xu F, Fei Z, Dai H et al (2022) Mesenchymal stem cell-derived extracellular vesicles with high PD-L1 expression for autoimmune diseases treatment. Adv Mater 34(1):e2106265